Format
Sort by

Send to

Choose Destination

Search results

Items: 16

1.

Translocase of inner mitochondrial membrane 44 alters the mitochondrial fusion and fission dynamics and protects from type 2 diabetes.

Wang Y, Katayama A, Terami T, Han X, Nunoue T, Zhang D, Teshigawara S, Eguchi J, Nakatsuka A, Murakami K, Ogawa D, Furuta Y, Makino H, Wada J.

Metabolism. 2015 Jun;64(6):677-88. doi: 10.1016/j.metabol.2015.02.004. Epub 2015 Feb 23.

PMID:
25749183
2.

Pemt deficiency ameliorates endoplasmic reticulum stress in diabetic nephropathy.

Watanabe M, Nakatsuka A, Murakami K, Inoue K, Terami T, Higuchi C, Katayama A, Teshigawara S, Eguchi J, Ogawa D, Watanabe E, Wada J, Makino H.

PLoS One. 2014 Mar 25;9(3):e92647. doi: 10.1371/journal.pone.0092647. eCollection 2014.

3.

Urinary angiotensinogen is a marker for tubular injuries in patients with type 2 diabetes.

Terami T, Wada J, Inoue K, Nakatsuka A, Ogawa D, Teshigawara S, Murakami K, Katayama A, Eguchi J, Makino H.

Int J Nephrol Renovasc Dis. 2013 Oct 22;6:233-40. doi: 10.2147/IJNRD.S51829. eCollection 2013.

4.

Urinary fetuin-A is a novel marker for diabetic nephropathy in type 2 diabetes identified by lectin microarray.

Inoue K, Wada J, Eguchi J, Nakatsuka A, Teshigawara S, Murakami K, Ogawa D, Terami T, Katayama A, Tone A, Iseda I, Hida K, Yamada M, Ogawa T, Makino H.

PLoS One. 2013 Oct 15;8(10):e77118. doi: 10.1371/journal.pone.0077118. eCollection 2013.

5.

Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease.

Kurose Y, Wada J, Kanzaki M, Teshigawara S, Nakatsuka A, Murakami K, Inoue K, Terami T, Katayama A, Watanabe M, Higuchi C, Eguchi J, Miyatake N, Makino H.

BMC Nephrol. 2013 Jan 22;14:23. doi: 10.1186/1471-2369-14-23.

6.

Visceral adipose tissue-derived serine proteinase inhibitor inhibits apoptosis of endothelial cells as a ligand for the cell-surface GRP78/voltage-dependent anion channel complex.

Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Hida K, Eguchi J, Ogawa D, Matsuki Y, Hiramatsu R, Yagita H, Kakuta S, Iwakura Y, Makino H.

Circ Res. 2013 Mar 1;112(5):771-80. doi: 10.1161/CIRCRESAHA.111.300049. Epub 2013 Jan 10. Erratum in: Circ Res. 2013 Apr 26;112(9):e98.

7.

Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex.

Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Hida K, Eguchi J, Horiguchi CS, Ogawa D, Matsuki Y, Hiramatsu R, Yagita H, Kakuta S, Iwakura Y, Makino H.

Diabetes. 2012 Nov;61(11):2823-32. doi: 10.2337/db12-0232. Epub 2012 Jul 26.

8.

Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population.

Teshigawara S, Wada J, Hida K, Nakatsuka A, Eguchi J, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Iseda I, Matsushita Y, Miyatake N, McDonald JF, Hotta K, Makino H.

J Clin Endocrinol Metab. 2012 Jul;97(7):E1202-7. doi: 10.1210/jc.2011-3297. Epub 2012 Apr 26.

PMID:
22539588
9.

A case of type 2 diabetes and metastatic liver cancer exhibiting hypercholesterolemia with abnormal lipoproteins.

Kanzaki M, Wada J, Nakatsuka A, Teshigawara S, Murakami K, Inoue K, Terami T, Katayama A, Nasu J, Yamamoto K, Makino H.

Intern Med. 2012;51(6):619-23. Epub 2012 Mar 15.

10.

Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes.

Kanzaki M, Wada J, Sugiyama K, Nakatsuka A, Teshigawara S, Murakami K, Inoue K, Terami T, Katayama A, Eguchi J, Akiba H, Yagita H, Makino H.

Endocrinology. 2012 Feb;153(2):612-20. doi: 10.1210/en.2011-1579. Epub 2011 Dec 20.

PMID:
22186414
11.

RXR antagonism induces G0 /G1 cell cycle arrest and ameliorates obesity by up-regulating the p53-p21(Cip1) pathway in adipocytes.

Nakatsuka A, Wada J, Hida K, Hida A, Eguchi J, Teshigawara S, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Ogawa D, Kagechika H, Makino H.

J Pathol. 2012 Apr;226(5):784-95. doi: 10.1002/path.3001. Epub 2012 Feb 9.

PMID:
21956786
12.

Two novel mutations of lecithin:cholesterol acyltransferase (LCAT) gene and the influence of APOE genotypes on clinical manifestations.

Katayama A, Wada J, Kataoka HU, Yamasaki H, Teshigawara S, Terami T, Inoue K, Kanzaki M, Murakami K, Nakatsuka A, Sugiyama H, Koide N, Bujo H, Makino H.

NDT Plus. 2011 Oct;4(5):299-302. doi: 10.1093/ndtplus/sfr091. Epub 2011 Jul 26.

13.

[Treatment of chronic rheumatoid arthritis. 3. Intra-articular injection of uronase].

Oara A, Terami T, Ezawa H.

Ryumachi. 1973 Oct;13(4):369-70. Japanese. No abstract available.

PMID:
4802712
14.

[Treatment of chronic rheumatoid arthritis. 2. Re-evaluation of gold therapy for rheumatoid arthritis].

Ezawa H, Oara A, Oguchi Y, Terami T.

Ryumachi. 1973 Oct;13(4):368. Japanese. No abstract available.

PMID:
4802711
15.

[Thyroid autoantibody and thyroid function in rheumatoid arthritis].

Takehisa Y, Miyoshi M, Suzuki S, Terami T, Oara A.

Ryumachi. 1973 Jan;12(4):342-7. Japanese. No abstract available.

PMID:
4714701
16.

[Comparison of clinical effects of gold thioglucose and gold sodium thiomalate].

Ezawa H, Gyoten Y, Oara A, Terami T, Okuma C.

Saishin Igaku. 1972 May;27(5):1002-8. Japanese. No abstract available.

PMID:
5040570
Items per page

Supplemental Content

Loading ...
Write to the Help Desk